Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
about
Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Cost-effectiveness analysis of ...... untreated mantle cell lymphoma
@ast
Cost-effectiveness analysis of ...... untreated mantle cell lymphoma
@en
Cost-effectiveness analysis of ...... untreated mantle cell lymphoma
@nl
type
label
Cost-effectiveness analysis of ...... untreated mantle cell lymphoma
@ast
Cost-effectiveness analysis of ...... untreated mantle cell lymphoma
@en
Cost-effectiveness analysis of ...... untreated mantle cell lymphoma
@nl
prefLabel
Cost-effectiveness analysis of ...... untreated mantle cell lymphoma
@ast
Cost-effectiveness analysis of ...... untreated mantle cell lymphoma
@en
Cost-effectiveness analysis of ...... untreated mantle cell lymphoma
@nl
P2093
P2860
P3181
P1433
P1476
Cost-effectiveness analysis of ...... untreated mantle cell lymphoma
@en
P2093
Divyagiri Seshagiri
Kerry Gairy
Pushpike Thilakarathne
P2860
P2888
P3181
P356
10.1186/S12885-016-2633-2
P407
P577
2016-01-01T00:00:00Z
P6179
1014933792